Empiric Antibiotic Therapy in Urinary Tract Infection in Patients with Risk Factors for Antibiotic Resistance in a German Emergency Department

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2018 Jan 28

PMID 29373965

Citations 49

Authors

Sebastian Bischoff

Thomas Walter

Marlis Gerigk

Matthias Ebert

Roger Vogelmann

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to identify clinical risk factors for antimicrobial resistances and multidrug resistance (MDR) in urinary tract infections (UTI) in an emergency department in order to improve empirical therapy.

Methods: UTI cases from an emergency department (ED) during January 2013 and June 2015 were analyzed. Differences between patients with and without resistances towards Ciprofloxacin, Piperacillin with Tazobactam (Pip/taz), Gentamicin, Cefuroxime, Cefpodoxime and Ceftazidime were analyzed with Fisher's exact tests. Results were used to identify risk factors with logistic regression modelling. Susceptibility rates were analyzed in relation to risk factors.

Results: One hundred thirty-seven of four hundred sixty-nine patients who met the criteria of UTI had a positive urine culture. An MDR pathogen was found in 36.5% of these. Overall susceptibility was less than 85% for standard antimicrobial agents. Logistic regression identified residence in nursing homes, male gender, hospitalization within the last 30 days, renal transplantation, antibiotic treatment within the last 30 days, indwelling urinary catheter and recurrent UTI as risk factors for MDR or any of these resistances. For patients with no risk factors Ciprofloxacin had 90%, Pip/taz 88%, Gentamicin 95%, Cefuroxime 98%, Cefpodoxime 98% and Ceftazidime 100% susceptibility. For patients with 1 risk factor Ciprofloxacin had 80%, Pip/taz 80%, Gentamicin 88%, Cefuroxime 78%, Cefpodoxime 78% and Ceftazidime 83% susceptibility. For 2 or more risk factors Ciprofloxacin drops its susceptibility to 52%, Cefuroxime to 54% and Cefpodoxime to 61%. Pip/taz, Gentamicin and Ceftazidime remain at 75% and 77%, respectively.

Conclusions: We identified several risk factors for resistances and MDR in UTI. Susceptibility towards antimicrobials depends on these risk factors. With no risk factor cephalosporins seem to be the best choice for empiric therapy, but in patients with risk factors the beta-lactam penicillin Piperacillin with Tazobactam is an equal or better choice compared to fluoroquinolones, cephalosporins or gentamicin. This study highlights the importance of monitoring local resistance rates and its risk factors in order to improve empiric therapy in a local environment.

Citing Articles

Recurrent Urinary Tract Infections in Older Adults Requiring Hospitalization in an Internal Medicine Ward.

Artero A, Lopez-Cruz I, Aguilera J, Piles L, Artero S, Eiros J Microorganisms. 2024; 12(11).

PMID: 39597504 PMC: 11596791. DOI: 10.3390/microorganisms12112114.

Proposal and clinical validation of a perioperative algorithm enhancing antimicrobial stewardship in substitution urethroplasty.

Marks P, Kranzbuhler B, Kluth L, Meyer C, Rosenbaum C, Ludwig T Asian J Urol. 2024; 11(4):604-610.

PMID: 39534006 PMC: 11551361. DOI: 10.1016/j.ajur.2024.01.003.

Antibiotic Resistance Trends in Uropathogens during the COVID-19 Pandemic in Western Romania: A Cross-Sectional Study.

Hogea E, Muntean A, Bratosin F, Bogdan I, Plavitu O, Fratutu A Antibiotics (Basel). 2024; 13(6).

PMID: 38927179 PMC: 11201005. DOI: 10.3390/antibiotics13060512.

Low Concentration of Wenyang Tonglin Decoction Promotes Conjugation and Transfer of Drug-Resistant Plasmids among Heterologous Strains.

Wang B, Bu H, Xia L, Jiang X, Tong Y Chin J Integr Med. 2024; 30(8):721-728.

PMID: 38816636 DOI: 10.1007/s11655-024-3904-4.

Urinary tract infections in older adults: associated factors for extended-spectrum beta-lactamase production.

Alkan S, Balkan I, Surme S, Bayramlar O, Kaya S, Karaali R Front Microbiol. 2024; 15:1384392.

PMID: 38784804 PMC: 11112107. DOI: 10.3389/fmicb.2024.1384392.

References

de With K, Allerberger F, Amann S, Apfalter P, Brodt H, Eckmanns T . Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases. Infection. 2016; 44(3):395-439. PMC: 4889644. DOI: 10.1007/s15010-016-0885-z. View

Flamm R, Sader H, Farrell D, Jones R . Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Diagn Microbiol Infect Dis. 2014; 80(3):233-8. DOI: 10.1016/j.diagmicrobio.2014.07.005. View

Vardi M, Kochavi T, Denekamp Y, Bitterman H . Risk factors for urinary tract infection caused by Enterobacteriaceae with extended-spectrum beta-lactamase resistance in patients admitted to internal medicine departments. Isr Med Assoc J. 2012; 14(2):115-8. View

Smithson A, Chico C, Ramos J, Netto C, Sanchez M, Ruiz J . Prevalence and risk factors for quinolone resistance among Escherichia coli strains isolated from males with community febrile urinary tract infection. Eur J Clin Microbiol Infect Dis. 2011; 31(4):423-30. DOI: 10.1007/s10096-011-1322-y. View

Zatorski C, Jordan J, Cosgrove S, Zocchi M, May L . Comparison of antibiotic susceptibility of Escherichia coli in urinary isolates from an emergency department with other institutional susceptibility data. Am J Health Syst Pharm. 2015; 72(24):2176-80. DOI: 10.2146/ajhp140832. View

Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W . Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004; 23(3):163-7. DOI: 10.1007/s10096-003-1084-2. View

Kratochwill L, Powers M, McGraw M, King L, ONeill J, Venkat A . Factors associated with ciprofloxacin-resistant Escherichia coli urinary tract infections in discharged ED patients. Am J Emerg Med. 2015; 33(10):1473-6. DOI: 10.1016/j.ajem.2015.07.047. View

Lee J, Oh C, Choi E, Lee H . The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates. Int J Infect Dis. 2013; 17(8):e638-43. DOI: 10.1016/j.ijid.2013.01.030. View

Wagenlehner F, Schmiemann G, Hoyme U, Funfstuck R, Hummers-Pradier E, Kaase M . [National S3 guideline on uncomplicated urinary tract infection: recommendations for treatment and management of uncomplicated community-acquired bacterial urinary tract infections in adult patients]. Urologe A. 2011; 50(2):153-69. DOI: 10.1007/s00120-011-2512-z. View

10.

Faine B, Harland K, Porter B, Liang S, Mohr N . A clinical decision rule identifies risk factors associated with antimicrobial-resistant urinary pathogens in the emergency department: a retrospective validation study. Ann Pharmacother. 2015; 49(6):649-55. DOI: 10.1177/1060028015578259. View

11.

Rosa R, Abbo L, Raney K, Tookes 3rd H, Supino M . Antimicrobial resistance in urinary tract infections at a large urban ED: Factors contributing to empiric treatment failure. Am J Emerg Med. 2016; 35(3):397-401. DOI: 10.1016/j.ajem.2016.11.021. View

12.

Khawcharoenporn T, Vasoo S, Ward E, Singh K . High rates of quinolone resistance among urinary tract infections in the ED. Am J Emerg Med. 2010; 30(1):68-74. DOI: 10.1016/j.ajem.2010.09.030. View

13.

Horcajada J, Shaw E, Padilla B, Pintado V, Calbo E, Benito N . Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre cohort study in the era of antimicrobial resistance. Clin Microbiol Infect. 2013; 19(10):962-8. DOI: 10.1111/1469-0691.12089. View

14.

Kundrapu S, Sunkesula V, Jury L, Cadnum J, Nerandzic M, Musuuza J . Do piperacillin/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization?. BMC Infect Dis. 2016; 16:159. PMC: 4835867. DOI: 10.1186/s12879-016-1514-2. View

15.

Gutkind G, Di Conza J, Power P, Radice M . β-lactamase-mediated resistance: a biochemical, epidemiological and genetic overview. Curr Pharm Des. 2012; 19(2):164-208. View

16.

Filiatrault L, McKay R, Patrick D, Roscoe D, Quan G, Brubacher J . Antibiotic resistance in isolates recovered from women with community-acquired urinary tract infections presenting to a tertiary care emergency department. CJEM. 2012; 14(5):295-305. DOI: 10.2310/8000.2012.120666. View

17.

Sader H, Castanheira M, Flamm R, Jones R . Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014. Antimicrob Agents Chemother. 2016; 60(7):4355-60. PMC: 4914695. DOI: 10.1128/AAC.00405-16. View

18.

Magiorakos A, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C . Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2011; 18(3):268-81. DOI: 10.1111/j.1469-0691.2011.03570.x. View

19.

Sotto A, De Boever C, Fabbro-Peray P, Gouby A, Sirot D, Jourdan J . Risk factors for antibiotic-resistant Escherichia coli isolated from hospitalized patients with urinary tract infections: a prospective study. J Clin Microbiol. 2001; 39(2):438-44. PMC: 87756. DOI: 10.1128/JCM.39.2.438-444.2001. View

20.

Bush K . A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents. 2015; 46(5):483-93. DOI: 10.1016/j.ijantimicag.2015.08.011. View